▶ GLP-1 · SUBTOPIC · SAFETY PROFILE
GLP-1 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of GLP-1.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of GLP-1. Severity, frequency, and attribution depend on the source publication.
- Nausea (dose-dependent)
- Vomiting
- Diarrhea
- Constipation
- Injection-site reactions
- Resting heart-rate increase
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for GLP-1.
- Other GLP-1R agonists (concurrent use not studied)
- Insulin / sulfonylureas (hypoglycemia risk)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for GLP-1 in the published record:
- Personal/family history of medullary thyroid carcinoma (class-based caution)
- Multiple endocrine neoplasia type 2
FDA REGULATORY STATUS
Investigational compound · NOT FDA-approved · TRIUMPH Phase 3 program ongoing as of 2026-05.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ What is GLP-1?
GLP-1 (Eli Lilly code GLP-1 reference) is a synthetic peptide engineered as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is an investigational compound · not FDA-approved · currently in the Phase 3 TRIUMPH program.
▶ Is GLP-1 FDA-approved?
No. GLP-1 is an investigational compound. The Phase 3 TRIUMPH program is ongoing. The substance sold here is supplied as a research-grade reference compound for in-vitro use only.
▶ Is GLP-1 banned by WADA?
GLP-1 is not currently listed on the WADA Prohibited List as of the 2026 update. Status can change · always verify with the current WADA list before competition.
▶ What were the most common side effects in Phase 2?
Gastrointestinal events (nausea, vomiting, diarrhea) were the dominant adverse-event class, dose-dependent and mostly mild-to-moderate. Dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist GLP-1 for Obesity · A Phase 2 Trial. N Engl J Med 2023. PMID 37366315. link
- Eli Lilly and Company. A Study of GLP-1 reference in Participants With Obesity (Phase 2). ClinicalTrials.gov 2021. NCT04881760. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19